LPMCs isolated from the inflamed mucosa of Crohn’s Disease patients had an increased expression of TGR5 compared to LPMCs from non-inflamed mucosa or healthy controls, and the use of TGR5 agonists could inhibit TNFa production [46]. This evidence concerns the gene GPBAR1 and Crohn disease.